Mair Therapeutics Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 1

Employees

  • Latest Deal Type
  • Seed

  • Investors
  • 2

Mair Therapeutics General Information

Description

Operator of TMEM175 agonist therapeutics intended to treat Parkinson's disease and related neurological disorders. The company offers drug candidates targeting TMEM175 pathways and lysosomal function mechanisms, enabling pharmaceutical researchers and healthcare institutions to study and develop treatments for neurodegenerative conditions.

Contact Information

Website
www.mairtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Toernooiveld 100
  • 6525 EC Nijmegen
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Toernooiveld 100
  • 6525 EC Nijmegen
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mair Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 13-Feb-2025 Completed Startup
To view Mair Therapeutics’s complete valuation and funding history, request access »

Mair Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of TMEM175 agonist therapeutics intended to treat Parkinson's disease and related neurological disorders. The c
Drug Discovery
Nijmegen, Netherlands
1 As of 2026

Brisbane, CA
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mair Therapeutics Competitors (2)

One of Mair Therapeutics’s 2 competitors is Tenvie, a Venture Capital-Backed company based in Brisbane, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tenvie Venture Capital-Backed Brisbane, CA
Lysoway Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 2 of 2 competitors. Get the full list »

Mair Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mair Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Oost NL Venture Capital Minority
Torrey Pines Investment Venture Capital Minority
To view Mair Therapeutics’s complete investors history, request access »

Mair Therapeutics FAQs

  • When was Mair Therapeutics founded?

    Mair Therapeutics was founded in 2024.

  • Where is Mair Therapeutics headquartered?

    Mair Therapeutics is headquartered in Nijmegen, Netherlands.

  • What is the size of Mair Therapeutics?

    Mair Therapeutics has 1 total employees.

  • What industry is Mair Therapeutics in?

    Mair Therapeutics’s primary industry is Drug Discovery.

  • Is Mair Therapeutics a private or public company?

    Mair Therapeutics is a Private company.

  • What is Mair Therapeutics’s current revenue?

    The current revenue for Mair Therapeutics is .

  • Who are Mair Therapeutics’s investors?

    Oost NL and Torrey Pines Investment have invested in Mair Therapeutics.

  • Who are Mair Therapeutics’s competitors?

    Tenvie and Lysoway Therapeutics are competitors of Mair Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process